Replimune Group Inc (NASDAQ:REPL) COO Colin Love sold 22,500 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $16.92, for a total value of $380,700.00.
Colin Love also recently made the following trade(s):
- On Thursday, October 31st, Colin Love sold 11,250 shares of Replimune Group stock. The stock was sold at an average price of $17.02, for a total value of $191,475.00.
- On Monday, September 23rd, Colin Love sold 11,250 shares of Replimune Group stock. The stock was sold at an average price of $17.05, for a total value of $191,812.50.
Shares of NASDAQ REPL traded down $0.13 during mid-day trading on Wednesday, hitting $13.55. 66,984 shares of the stock traded hands, compared to its average volume of 77,466. The company has a debt-to-equity ratio of 0.16, a quick ratio of 9.85 and a current ratio of 9.85. The stock has a fifty day moving average price of $14.70 and a 200-day moving average price of $13.24. The company has a market cap of $444.92 million, a price-to-earnings ratio of -10.19 and a beta of 3.08. Replimune Group Inc has a 52 week low of $8.88 and a 52 week high of $18.25.
Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Monday, November 11th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). As a group, sell-side analysts predict that Replimune Group Inc will post -1.38 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Redmile Group LLC boosted its position in Replimune Group by 0.7% during the 3rd quarter. Redmile Group LLC now owns 2,213,417 shares of the company’s stock valued at $30,766,000 after acquiring an additional 16,414 shares in the last quarter. BlackRock Inc. boosted its position in shares of Replimune Group by 8.2% in the 2nd quarter. BlackRock Inc. now owns 1,015,225 shares of the company’s stock worth $14,883,000 after purchasing an additional 76,540 shares in the last quarter. Foresite Capital Management III LLC boosted its position in shares of Replimune Group by 4.0% in the 2nd quarter. Foresite Capital Management III LLC now owns 779,656 shares of the company’s stock worth $11,430,000 after purchasing an additional 30,002 shares in the last quarter. Emerald Mutual Fund Advisers Trust boosted its position in shares of Replimune Group by 3.0% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 733,404 shares of the company’s stock worth $10,194,000 after purchasing an additional 21,634 shares in the last quarter. Finally, Emerald Advisers LLC lifted its position in Replimune Group by 5.2% during the 3rd quarter. Emerald Advisers LLC now owns 728,890 shares of the company’s stock worth $10,132,000 after acquiring an additional 35,712 shares during the period. 56.99% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages recently issued reports on REPL. Chardan Capital reiterated a “buy” rating and issued a $28.00 target price on shares of Replimune Group in a report on Thursday, October 24th. HC Wainwright reissued a “buy” rating and issued a $26.00 price target on shares of Replimune Group in a research report on Monday, September 30th. ValuEngine raised Replimune Group from a “hold” rating to a “buy” rating in a research report on Tuesday, November 19th. Wedbush decreased their target price on Replimune Group from $30.00 to $12.50 and set an “outperform” rating for the company in a research report on Wednesday, November 20th. Finally, Zacks Investment Research downgraded Replimune Group from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $23.25.
Replimune Group Company Profile
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
See Also: Elliott Wave Theory
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.